Показано 0 из 0
Дата |
---|
10.05.2024 |
09.05.2024 |
08.05.2024 |
07.05.2024 |
06.05.2024 |
03.05.2024 |
02.05.2024 |
01.05.2024 |
30.04.2024 |
29.04.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
4.35
|
4.76
|
4.8999
|
4.57
|
4.8999
|
4.57
|
|
|
133 547.32
|
169.00
|
4.56
|
4.90
|
4.6543
|
4.545
|
4.8384
|
4.71
|
|
|
166 244.63
|
307.00
|
4.65
|
4.94
|
4.5287
|
4.52
|
4.77
|
4.65
|
|
|
181 013.03
|
291.00
|
4.65
|
4.94
|
4.75
|
4.63
|
4.98
|
4.68
|
|
|
373 861.76
|
567.00
|
4.70
|
5.05
|
5.03
|
4.44
|
5.04
|
4.71
|
|
|
273 976.22
|
468.00
|
5.00
|
5.40
|
4.84
|
4.7203
|
5.38
|
5.09
|
|
|
834 734.08
|
809.00
|
4.81
|
4.85
|
4.95
|
4.70
|
5.18
|
4.76
|
|
|
239 105.62
|
311.00
|
4.56
|
4.70
|
4.70
|
4.37
|
4.99
|
4.83
|
|
|
250 833.25
|
380.00
|
4.98
|
5.10
|
4.40
|
4.35
|
5.12
|
4.74
|
|
|
1 072 449.04
|
1 203.00
|
4.23
|
4.52
|
4.49
|
4.41
|
4.58
|
4.452
|
|
|
98 177.32
|
173.00
|
Synaptogenix, Inc. operates as a biopharmaceutical company. The Company focuses on developing a product platform for the treatment of Alzheimer's disease, as well as evaluates therapeutic applications of bryostatin for neurodegenerative, cognitive, and dysfunctions such as fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases.